主动脉瓣狭窄的药物治疗
该综述系统回顾了主动脉瓣狭窄药物治疗的研究,重点评估降脂治疗、降压药物和抗钙化治疗三大类药物的临床证据。文章指出,有症状的重度主动脉瓣狭窄唯一能改善生存的治疗是主动脉瓣置换,而药物理论上有望延缓狭窄进展并减轻左室重构,但现有证据需批判性评价。
要点
- 有症状重度主动脉瓣狭窄唯一证实改善生存的治疗为主动脉瓣置换。
- 降脂、降压和抗钙化治疗是研究最多的药物类别,但证据有限。
- 无症状潜伏期是药物干预的潜在窗口,需进一步临床研究验证。
核心结论
- 有症状重度主动脉瓣狭窄预后差,唯一证实改善生存的治疗是主动脉瓣置换;药物治疗在理论上可延缓狭窄进展并改善临床结局,但现有证据尚不充分。
研究设计与样本
- 本研究为系统综述,聚焦主动脉瓣狭窄患者药物治疗的研究,对降脂治疗、降压药物和抗钙化治疗三大类药物进行了深入回顾与批判性评价。
主要发现
- 降脂治疗、降压药物和抗钙化治疗是主动脉瓣狭窄药物治疗中研究最多的药物类别,综述对其临床前和临床证据进行了批判性评价。
临床怎么用
- 有症状重度主动脉瓣狭窄应首选主动脉瓣置换;药物治疗目前不能替代换瓣,需在无症状潜伏期探索延缓进展的策略。
局限性
- 现有药物治疗证据有限,缺乏能证实延缓主动脉瓣狭窄进展或改善硬终点的药物;综述未报告具体样本量、效应值或P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Untreated, severe, symptomatic aortic stenosis is associated with a dismal prognosis. The only treatment shown to improve survival is aortic valve replacement; however, before symptoms occur, aortic stenosis is preceded by a silent, latent phase characterized by a slow progression at the molecular, cellular, and tissue levels. In theory, specific medical therapy should halt aortic stenosis progression, reduce its hemodynamic repercussions on left ventricular function and remodeling, and improve clinical outcomes. In the present report, we performed a systematic review of studies focusing on the medical treatment of patients with aortic stenosis. Lipid-lowering therapy, antihypertensive drugs, and anticalcific therapy have been the main drug classes studied in this setting and are reviewed in depth. A critical appraisal of the preclinical and clinical evidence is provided, and future research avenues are presented.
引用
- Marquis-Gravel G, Redfors B, Leon MB, et al. Medical Treatment of Aortic Stenosis. Circulation. 2016. PMID: 27895025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。